Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA.
Department of Laboratory Medicine and Pathology, University of Washington, Seattle, USA; Department of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Gynecol Oncol. 2024 Nov;190:18-27. doi: 10.1016/j.ygyno.2024.07.690. Epub 2024 Aug 10.
Individuals with germline BRCA1 and BRCA2 pathogenic variants (BRCA carriers) are at high risk of developing high grade serous ovarian carcinoma (HGSC). HGSC is predominantly driven by TP53 mutations, but mutations in this gene are also commonly found in non-cancerous tissue as a feature of normal human aging. We hypothesized that HGSC predisposition in BRCA carriers may be related to increased TP53 somatic evolution, which could be detectable by ultra-deep sequencing of TP53 mutations in gynecological liquid biopsies.
Duplex sequencing was used to identify TP53 mutations with high sensitivity in peritoneal washes and cervical liquid-based cytology (LBC) collected at surgery from 60 individuals including BRCA1 and BRCA2 carriers, and non-carriers. TP53 mutation pathogenicity was compared across groups and with TP53 cancer mutations.
TP53 mutations were more abundant in cervical LBC than in peritoneal washes but increased with age in both sample types. In peritoneal washes, but not in cervical LBC, pathogenic TP53 mutation burden was increased in BRCA1 carriers compared to non-carriers, independently of age. Five individuals shared identical pathogenic TP53 mutations in peritoneal washes and cervical LBC, but not in blood.
Ultra-deep sequencing of TP53 mutations in peritoneal washes collected at surgery reveals increased burden of pathogenic TP53 mutations in BRCA1 carriers. This excess of pathogenic TP53 mutations might be linked to the elevated risk of HGSC in these individuals. In some patients, concordant TP53 mutations were found in peritoneal washes and cervical LBCs, but the cell of origin remains unknown and deserves further investigation.
携带胚系 BRCA1 和 BRCA2 致病性变异(BRCA 携带者)的个体发生高级别浆液性卵巢癌(HGSC)的风险很高。HGSC 主要由 TP53 突变驱动,但该基因的突变也常见于非癌组织,作为正常人类衰老的特征。我们假设 BRCA 携带者的 HGSC 易感性可能与 TP53 体细胞进化增加有关,这可以通过对妇科液基细胞学(LBC)和腹腔冲洗液中 TP53 突变进行超深度测序来检测。
采用双等位基因测序方法,在 60 名个体的手术中收集的腹腔冲洗液和宫颈 LBC 中,以高灵敏度鉴定 TP53 突变,包括 BRCA1 和 BRCA2 携带者和非携带者。比较了各组之间以及与 TP53 癌症突变之间的 TP53 突变致病性。
TP53 突变在宫颈 LBC 中的丰度高于腹腔冲洗液,但在两种样本类型中均随年龄增加而增加。在腹腔冲洗液中,但在宫颈 LBC 中,BRCA1 携带者的致病性 TP53 突变负担与非携带者相比增加,与年龄无关。5 名个体的腹腔冲洗液和宫颈 LBC 中存在相同的致病性 TP53 突变,但在血液中不存在。
手术时收集的腹腔冲洗液中 TP53 突变的超深度测序显示 BRCA1 携带者中致病性 TP53 突变负担增加。这些个体中过多的致病性 TP53 突变可能与 HGSC 的风险增加有关。在一些患者中,在腹腔冲洗液和宫颈 LBC 中发现了一致的 TP53 突变,但细胞起源尚不清楚,值得进一步研究。